NanoViricides

NNVC

Market cap $20.2M

NanoViricides (NYSE-A:NNVC) said on Monday it signed a master services agreement with regulatory consulting firm Only Orphans Cote LLC to support the company's orphan drug strategy for its broad-spectrum antiviral candidate NV-387. The firm, founded by former US Food and Drug Administration official Dr Timothy Cote, will help develop and prosecute orphan drug designation applications for NV-387 at the FDA's Office of Orphan Products, NanoViricides said.

SHELTON, CONNECTICUT / ACCESS Newswire / December 1, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announced today that it has signed a Master Services Agreement (MSA) with Only Orphans Cote, LLC, ("OOC") a regulatory consultant firm founded by Dr. Timothy Cote.

NanoViricides (NYSE-A:NNVC) is advancing its broad-spectrum antiviral NV-387, backed by new financing that strengthens its balance sheet and supports regulatory progress toward Phase II trials for monkeypox in Central Africa. In its quarterly report for the quarter ended September 30, 2025, the clinical-stage biotech company said NV-387 is engineered to resist viral escape.

SHELTON, CONNECTICUT / ACCESS Newswire / November 17, 2025 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter ending September 30, 2025 with the Securities and Exchange Commission (SEC) on Friday, November 14, 2025.

SHELTON, CONNECTICUT / ACCESS Newswire / November 14, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced that it will be presenting today, Friday, November 14th, at 11:25am ET at the Pharma Partnering Summit 2025 held at the Hilton Boston Logan Airport in Boston, MA. Event Information: Event NanoViricides Presentation at the Pharma Partnering Summit 2025 in Boston, MA Time & Date 11:25 am to 11:45 am ET on Friday, November 14, 2025 Location Hilton Boston Logan Airport, Boston, MA Anil R.

NanoViricides (NYSE-A:NNVC) said on Thursday it had closed a $6 million registered direct offering with a single healthcare institutional investor to support working capital and general corporate purposes. The Connecticut-based biotechnology company sold about 3.57 million shares of common stock, or equivalents, at $1.68 per share.

SHELTON, CONNECTICUT / ACCESS Newswire / November 12, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), today announced the closing of its previously announced securities purchase agreement with a single healthcare institutional investor for the purchase and sale of 3,571,429 shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $1.68 per share in a registered direct offering (the "Offering"). The gross proceeds from the Offering are approximately $6 million, before deducting placement agent commissions and other offering expenses.

NanoViricides (NYSE-A:NNVC) said on Tuesday it has entered into a securities purchase agreement with a single healthcare institutional investor to raise about $6 million through a registered direct offering. The company will sell 3.57 million shares of common stock, or equivalents, at $1.68 per share.

SHELTON, CONNECTICUT / ACCESS Newswire / November 11, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), today announced that it has entered into a securities purchase agreement with a single healthcare institutional investor for the purchase and sale of 3,571,429 shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $1.68 per share in a registered direct offering (the "Offering"). The gross proceeds from the Offering are expected to be approximately $6 million, before deducting placement agent commissions and other offering expenses.

NanoViricides (NYSE-A:NNVC) announced that it has received approval to begin its Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo (DRC).  The clinical stage biotechnology company said the proposed Phase II clinical trial to evaluate safety and effectiveness of NV-387 for the treatment of patients with MPox disease caused by hMPXV infection is now cleared to proceed subject to filing of certain documents.